Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
PF-219,061
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Routes of administration |
Nasal |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C13H19NO2 |
Molar mass | 221.300 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials.
See also
- ABT-670
- ABT-724
- Cabergoline
- Bremelanotide
- Flibanserin
- Intrinsa
- Melanotan II
- OSU-6162
- PF-592,379
- Pramipexole
- Tibolone
- UK-414,495